{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:39:19Z","timestamp":1792179559461,"version":"4.4.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100014131","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012322","name":"Michael Garron Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Spironolactone and cyproterone acetate (CPA) are the two main antiandrogen medications used in feminizing hormone therapy in transgender women. Previous studies have suggested that these two agents might have opposite effects on high-density lipoprotein (HDL) level when used in this context, and limited data have suggested CPA increases prolactin more than spironolactone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To compare the effects of spironolactone and CPA on HDL and prolactin serum concentrations in transgender women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective chart review was conducted at three clinical sites in Toronto, Ontario, Canada. Patients were selected if they (i) identified as a transgender woman, (ii) had newly started spironolactone or CPA with estrogen or restarted spironolactone or CPA after a washout period of at least 6 months, and (iii) had not used other antiandrogens within the previous 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome Measures<\/jats:title><jats:p>HDL and prolactin concentrations between the two treatment groups at baseline and at 12 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty-two patients were included in the spironolactone group and 31 patients were included in the CPA group. Baseline HDL and prolactin levels were not significantly different between the two groups. At 12 months, HDL increased by 0.10 mmol\/L (SD = 0.24) in the spironolactone group but decreased by 0.07 mmol\/L (SD = 0.21) in the CPA group (P = .002). The difference remained significant after adjusting for baseline HDL, use of lipid-lowering drugs, and age. The change in prolactin was +3.10 \u03bcg\/L (SD = 5.70) in the spironolactone group and +11.8 \u03bcg\/L (SD = 8.63) in the CPA group (P &amp;lt; 0.001). This difference also remained significant after adjusting for baseline prolactin level.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These data suggest that spironolactone use in transgender women increases HDL levels and that CPA has the opposite effect. CPA also is associated with a larger increase in prolactin. These factors should be considered when choosing between these two antiandrogen agents.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.jsxm.2016.09.012","type":"journal-article","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T22:30:23Z","timestamp":1475361023000},"page":"1765-1772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women"],"prefix":"10.1093","volume":"13","author":[{"given":"Raymond","family":"Fung","sequence":"first","affiliation":[{"name":"Michael Garron Hospital , Toronto, ON , Canada"},{"name":"Toronto East Health Network , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hellstern-Layefsky","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , Toronto, ON , Canada"},{"name":"University of Toronto , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Tastenhoye","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , Dublin, , Ireland"},{"name":"Royal College of Surgeons in Ireland , Dublin, , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iliana","family":"Lega","sequence":"additional","affiliation":[{"name":"Women\u2019s College Hospital , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Steele","sequence":"additional","affiliation":[{"name":"St. Michael\u2019s Hospital , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,11,1]]},"reference":[{"key":"2023041406284264000_","article-title":"How many people are lesbian, gay, bisexual, and transgender?","volume-title":"Williams Institute","author":"Gates"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1210\/jc.2009-0345","article-title":"Endocrine treatment of transsexual persons: an Endocrine Society Clinical Practice Guideline","volume":"94","author":"Hembree","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1210\/jc.2002-021967","article-title":"Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects","volume":"88","author":"Moore","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-10-1038","article-title":"A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones","volume":"164","author":"Asscheman","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1111\/j.1743-6109.2012.02876.x","article-title":"Long-term evaluation of cross-sex hormone treatment in transsexual persons","volume":"9","author":"Wierckx","year":"2012","journal-title":"J Sex Med"},{"key":"2023041406284264000_","article-title":"Guidelines and protocols for comprehensive primary health care for trans clients","volume-title":"Sherbourne Health Centre","author":"Greenaway"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jama.2012.165234","article-title":"Management of transgenderism","volume":"309","author":"Spack","year":"2013","journal-title":"JAMA"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/jsm.12571","article-title":"Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European Network for the Investigation of Gender Incongruence: Endocrine Treatment of Trans Persons","volume":"11","author":"Wierckx","year":"2014","journal-title":"J Sex Med"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/AOG.0000000000000692","article-title":"Effects of cross-sex hormone treatment on transgender women and men","volume":"125","author":"Deutsch","year":"2015","journal-title":"Obstet Gynecol"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2265.2009.03632.x","article-title":"Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses: cardiovascular effects of sex steroid therapy in transsexuals","volume":"72","author":"Elamin","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1111\/j.1743-6109.2011.02311.x","article-title":"Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals","volume":"8","author":"Ott","year":"2011","journal-title":"J Sex Med"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF01579291","article-title":"Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism","volume":"18","author":"Prior","year":"1989","journal-title":"Arch Sex Behav"},{"key":"2023041406284264000_","first-page":"583","article-title":"Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals","volume":"28","author":"Asscheman","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0026-0495(89)90233-3","article-title":"Mortality and morbidity in transsexual patients with cross-gender hormone treatment","volume":"38","author":"Asscheman","year":"1989","journal-title":"Metabolism"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2265.1997.2601068.x","article-title":"Mortality and morbidity in transsexual subjects treated with cross-sex hormones","volume":"47","author":"van Kesteren","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/A:1018704630036","article-title":"A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients","volume":"27","author":"Schlatterer","year":"1998","journal-title":"Arch Sex Behav"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.fertnstert.2010.01.076","article-title":"Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual","volume":"94","author":"Garc\u00eda-Malpartida","year":"2010","journal-title":"Fertil Steril"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","DOI":"10.1111\/and.12666","article-title":"Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons","volume-title":"Andrologia","author":"Nota"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2265.2003.01753.x","article-title":"Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects","volume":"58","author":"Elbers","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJM198911093211907","article-title":"High-density lipoprotein\u2014the clinical implications of recent studies","volume":"321","author":"Gordon","year":"1989","journal-title":"N Engl J Med"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/0002-8703(83)90174-6","article-title":"Cardiovascular disease and multifactorial risk: challenge of the 1980s","volume":"106","author":"Castelli","year":"1983","journal-title":"Am Heart J"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00256895","article-title":"Effect of cyproterone\/acetate (SH-714) on plasma prolactin in patients with prostatic cancer","volume":"9","author":"Holub","year":"1981","journal-title":"Urol Res"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0277-5379(98)90011-6","article-title":"Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer","volume":"24","author":"Willemse","year":"1988","journal-title":"Eur J Cancer Clin Oncol"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0010-7824(80)80017-5","article-title":"Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men","volume":"21","author":"Moltz","year":"1980","journal-title":"Contraception"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00219991","article-title":"Effect of cyproterone acetate on prolactin secretion in the female Rhesus monkey","volume":"183","author":"Herbert","year":"1977","journal-title":"Cell Tissue Res"},{"issue":"Suppl.","key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/0269881107082624","article-title":"Adverse effects of prolactin in rodents and humans: breast and prostate cancer","volume":"22","author":"Harvey","year":"2008","journal-title":"J Psychopharmacol"},{"key":"2023041406284264000_","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-04-1870","article-title":"Plasma prolactin concentrations and risk of postmenopausal breast cancer","volume":"64","author":"Tworoger","year":"2004","journal-title":"Cancer Res"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609516304210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609516304210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/13\/11\/1765\/49886256\/jsm_13_11_1765.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/13\/11\/1765\/49886256\/jsm_13_11_1765.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T18:29:17Z","timestamp":1718821757000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/13\/11\/1765\/6940504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,1]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2016.09.012","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,11]]},"published":{"date-parts":[[2016,11,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2016.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}